Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

False Scientifically refuted Certainty of evidence: moderate provisional C-CAN-04

Cancer will respond to the Tayebat system; a patient with a malignant tumour should start the system now (diet as cancer treatment).

Safety note: Do not refuse, stop or delay recommended cancer treatment (surgery, chemotherapy, radiotherapy, hormone or targeted therapy) in favour of a diet. In curable cancers, replacing standard treatment with alternative approaches is associated with a markedly higher risk of death (I-CHM-03, I-CHM-04, I-CAN-101, I-CAN-102), and even four-week delays are associated with higher mortality (I-CHM-07). Late effects are real and are managed by survivorship and cardio-oncology care; discuss them with the treating oncology team. Nutrition can be adapted alongside treatment with the oncology team. No individual medical advice is given here.
In short: This claim is false. No diet, including the Tayebat system, has been shown to shrink or cure cancer, and patients who use alternatives instead of standard treatment die markedly more often (e.g. breast cancer: adjusted hazard ratio 3.67).
Conclusion: This claim is false: no diet, including the Tayebat system, has been shown to treat cancer, and using it instead of standard treatment is associated with markedly higher mortality.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

زي ما انا اكتشفت ان السرطان هيستجيب لي شغلي اه هيستجيب لي شغلي طبعا

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Cancer will respond to the Tayebat system; a patient with a malignant tumour should start the system now (diet as cancer treatment).

Origin

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
السرطان ١ (Open source)
Published
26 January 2025
Timestamp
0:44:36 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Attribution uncertainty
Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
Population concerned

Cancer patients

Geographic restriction by Elawady

none found

Diverging source versions

ايوه طبعا يمشي على النظام اللي عنده ورم خبيث ده يمشي على النظام من دلوقتي

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
السرطان ١ (Open source)
Published
26 January 2025
Timestamp
0:19:06 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)

خفف سرطانات خفف

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
Dr.D Clinics - Diaa Al Awady is live! مقدمة عن الدهون ⧸ الغشاء الخلوي (Open source)
Published
9 April 2025
Timestamp
not available (transcript has no timings)

تنبيه: لا يُعد هذا دليلاً لعلاج السرطان. المرضى تحت إشراف فريق أورام.

Source status
Third-party site (unofficial)
Attribution
Third-party site (unofficial)
Origin
https://mytayibat.com/mytayibat-cancer

ايه النظام المناسب للقضاء على سرطان المخ يا باشا هو نظام واحد انا ما اخترعتش 600 نظام [أصوات شخير] يعني انا ما اخترعتش 600 نظام هو نظام واحد هو نظام الطيبات اا ونظام الطيبات هو مش نظام بمعنى اصح هو تكنيك وانا اسف كلمه تكنيك دي لو

Asked which system is suitable for eliminating brain cancer, he answered that there is only one system, the Tayebat system, which is a technique based on forbidding some foods and allowing others.

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا تصليح مفاهيم (Open source)
Published
31 March 2026
Timestamp
0:13:42 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Attribution uncertainty
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

Scientific assessment

False – The statement contradicts the robust evidence.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

The diet treats or controls cancer.

2. What is demonstrably correct?

Nutrition matters during cancer (e.g., preventing malnutrition) and healthy weight lowers some cancer risks; using a diet alongside treatment is not by itself harmful (I-CHM-04 shows risk was mediated by refusal).

3. What is wrong or exaggerated?

No evidence that the Tayebat diet shrinks or cures cancer; testimonies in the videos are unverifiable and often involve prior surgery or chemotherapy. Alternative-only management of curable cancers was associated with HR 2.50 for death (I-CHM-03). In patients who were eventually treated, each 4-week delay within the studied range of about 4-16 weeks was associated with 6-13% higher mortality for many indications (observational; I-CHM-07); the longer delays of trying a diet first were not studied, and the authors warn against extrapolating beyond 16 weeks.

4. What remains unclear?

Long-term outcomes of the patients presented in the videos.

5. Which studies support it?

None for diet as treatment. In a randomised trial, a low-fat diet added to conventional treatment after breast cancer surgery was associated with somewhat fewer relapses (9.8% vs 12.4%; HR 0.76, borderline; I-CAN-131). A small randomised trial of a supervised ketogenic diet added to chemotherapy for metastatic pancreatic cancer showed non-significant trends toward longer survival (I-CAN-125); ketogenic diets alongside standard care improved some metabolic and symptom measures (I-CAN-103); CAM combined with full treatment was not associated with higher mortality in GI cancers (I-CAN-102). None of this supports replacing or delaying treatment. The registry 'CAM' studies capture non-medical alternative treatment rather than supportive complementary care (I-CAN-128).

6. Which studies contradict it?

I-CHM-03, I-CHM-04, I-CHM-07, I-CAN-101 (breast cancer, CAM alone AHR 3.67), I-CAN-102 (GI cancers, CAM alone aHR 1.86), I-CAN-129 (refusal of colon cancer surgery, HR 3.41), I-CAN-104 (ketogenic-diet RCTs: insufficient evidence), I-CAN-105 (ASCO: diet evidence very limited), I-CAN-106 (NCI: no diet proven to control cancer).

7. What applies to Germany and Europe?

Not region-specific; the evidence on the harms of replacing or delaying cancer treatment (I-CHM-03, I-CHM-04, I-CHM-07) applies equally in Germany and Europe.

8. What is known about Egypt?

Not region-specific; the same risks apply. The videos address mainly Egyptian and Arab patients, so the claim is practically relevant there.

9. What practical conclusion is appropriate?

A diet may be discussed as supportive care with the oncology team, never as a replacement.

Assessment details

Rationale for certainty of evidence

No clinical study of the Tayebat system in cancer exists (none found); indirect but consistent evidence shows excess mortality when diet/alternative approaches replace treatment. Certainty is moderate because the evidence on this specific diet is indirect.

Source quality

Machine transcript; third-party site disagrees.

Regional transferability

High.

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.

Research question: In people with a malignant tumour, does adopting the Tayebat diet (or any diet) instead of, or before, standard oncological treatment control the cancer, and how does replacing or delaying standard treatment affect survival?

Research question in detail (PICO)
Population
Patients with malignant tumours
Intervention or exposure
Tayebat system / diet-based or other alternative management used instead of or before standard treatment
Comparison
Standard oncological treatment (surgery, chemotherapy, radiotherapy, endocrine, targeted, immunotherapy)
Geographic scope
universal biology
Outcomes
  • Overall survival
  • Tumour response / cancer control
  • Treatment delay

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

  • A low-fat diet alongside breast cancer treatment may reduce relapse

    Chlebowski RT et al.. J Natl Cancer Inst 2006 · PMID 17179478 · DOI 10.1093/jnci/djj494 Randomised controlled trialabstract checkednewly added

    WINS randomised trial: a low-fat diet added to conventional treatment after breast cancer surgery.

    Actual result
    Relapse 9.8% vs 12.4%; HR 0.76 (0.60-0.98); log-rank P=.077, Cox P=.034
    Methodological quality
    moderate (large RCT; interim, open-label, borderline)
    Relevance
    indirect: diet as an adjunct to treatment, a different diet
    Limitations
    Borderline significance; not a replacement of treatment.

    Original publication

  • Ketogenic diet added to chemotherapy for pancreatic cancer: early trial

    Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343 Randomised controlled trialabstract checkednewly added

    Randomised phase II trial: a medically supervised ketogenic diet added to chemotherapy for metastatic pancreatic cancer.

    Actual result
    Median PFS 8.5 vs 6.2 months, HR 0.53 (0.21-1.37); OS 13.7 vs 10.2 months, HR 0.58 (0.25-1.37); not statistically significant
    Methodological quality
    moderate design, low precision (n=32, one-sided alpha 0.20, commercial COI)
    Relevance
    indirect: diet added to chemotherapy, not instead of it; different diet
    Limitations
    Unconfirmed trend; small.

    Original publication

  • Ketogenic diets in cancer patients: some metabolic benefits

    Zhang M et al.. Front Nutr 2025 · PMID 40756563 · DOI 10.3389/fnut.2025.1535921 Meta-analysisabstract checkednewly added

    Meta-analysis of ketogenic diets in cancer patients (mostly alongside standard care) found better metabolic and some symptom outcomes.

    Actual result
    Reduced fat mass, insulin, glucose, fatigue and insomnia; no survival or tumour outcomes in abstract.
    Methodological quality
    low-moderate (surrogate outcomes, small studies)
    Relevance
    indirect: a different diet, used as an adjunct, not a replacement
    Limitations
    No evidence on tumour control or survival; not the Tayebat diet.

    Original publication

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Diet is not a treatment for cancer; replacing or delaying standard treatment with a diet or other alternatives is associated with markedly higher mortality.

Why some studies weigh more

Survival data on replacement or refusal of treatment (I-CHM-03, I-CAN-101, I-CAN-102, I-CHM-04, I-CAN-129) weigh most because they address the decision the claim recommends; they come from one registry (NCDB) and partly overlap, so they count as one replicated source; a 2026 critique (I-CAN-128) shows that the NCDB variable captures registry-coded non-medical alternative treatment (not supportive complementary care) and that some analytic details are unclear, which limits the size estimates but not the direction, and it explicitly affirms the concern about replacing treatment. Randomised trials of diets added to standard treatment (I-CAN-131 low-fat diet, borderline fewer relapses; I-CAN-125 ketogenic diet, unconfirmed trend) are the fair 'supporting' side: nutrition may help alongside treatment, which is the opposite of the claim's practical advice. RCT-level diet evidence (I-CAN-104) and the ASCO guideline (I-CAN-105) show no diet has proven cancer control. Ketogenic-diet data (I-CAN-103) concern adjunct use and surrogate outcomes.

Is a causal relationship established? Probable Randomising patients to forgo curative treatment would be unethical; large, consistent adjusted hazard ratios across cancers, a dose-like gradient (no treatment ~ CAM alone > partial > full treatment) and the known efficacy of standard treatment from RCTs (I-CHM-01, I-CHM-05) make a causal harm probable.

Remaining uncertainty

No study of the Tayebat system itself; NCDB misclassification; effect of diets used strictly as adjuncts.

Justified conclusion

This claim is false: no diet, including the Tayebat system, has been shown to treat cancer, and using it instead of or before standard treatment is associated with substantially higher mortality.

Why do studies seem to disagree?

Apparent conflict between ketogenic-diet meta-analyses (I-CAN-103 positive, I-CAN-104 largely null) reflects different inclusion criteria (non-randomised vs RCT-only) and surrogate endpoints; neither addresses replacement of treatment. NCDB studies agree (Johnson 2018, Ayoade 2026, Ekenze 2026) but share one database. Ekenze found no excess mortality with CAM combined with treatment in GI cancers, whereas Ayoade found excess mortality in breast cancer, apparently because combination users skipped radiation and endocrine therapy - both support the same conclusion: harm arises from forgoing treatment. Jeitler 2026 (I-CAN-128) criticises the NCDB studies for construct validity, immortal-time handling and missing tumour-biology adjustment; this weakens precise effect sizes and any inference about supportive complementary care, but not the conclusion about replacing treatment. The positive trend in I-CAN-125 concerns a diet added to chemotherapy and therefore does not conflict with the harm of replacing treatment.

Does this depend on the country?
General biological effects
Universal human biology; applies in Egypt, Germany and elsewhere.
Eating habits
The Tayebat diet has not been studied in cancer anywhere; Egyptian/Arab patients are the main audience of the videos.
Origin of the food
Not relevant.
Contaminants
Not relevant.
National production conditions
Not relevant.
Legal rules
Not relevant.
Actual monitoring data
No Egyptian data on alternative-medicine use and survival were found.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • CI log-symmetry of AHRs; unadjusted absolute survival difference; stage confounding – AHR CIs symmetric (ratio 0.99); unadjusted 5-y OS difference 25.3 points, partly confounded by stage (31.8% vs 18.1% stage III-IV); adjusted absolute risks not reported, NNH not derivable. recalculated
  • CI log-symmetry; size of exposed group – Symmetric; CAM-only 0.013% of cohort -> imprecise estimate. recalculated
  • CI symmetry; absolute risk; robustness – HR CI symmetric; crude relapse 9.8% vs 12.4%, ARR 2.5 points, NNT about 39 over ~5 years; log-rank P=.077 vs Cox P=.034 -> fragile. recalculated
  • CI symmetry; one-sided vs two-sided testing – Symmetric; two-sided p about 0.18/0.21 from the CIs; one-sided alpha 0.20 screening design -> no confirmed effect. recalculated
  • CI log-symmetry – Reported CI 3.12-3.60 asymmetric around 3.41 (ratio 0.61); possible reporting/rounding error, not resolvable from the abstract; Medicaid OR upper limit 43.77 implausible (not used). recalculated
  • Independence of NCDB cohorts – Johnson, Ayoade and Ekenze share the NCDB with 3-4 overlapping diagnosis years -> counted as one replicated data source. recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Overall survival when diet/alternative medicine replaces standard treatment
Starting level
low (observational studies)
Reasons for downgrading
  • indirectness (no Tayebat-specific data; NCDB category is registry-coded non-medical treatment, I-CAN-128)
  • risk of bias (residual confounding; unclear immortal-time handling)
Reasons for upgrading
  • large effect (HR 2.5-3.7)
  • dose-response-like gradient (full > partial > no treatment)
  • consistency across cancers and periods
Result
moderate

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • US National Cancer Institute: Complementary and Alternative Medicine (CAM) (2024) · Original publication
    Alternative medicine is used instead of standard treatment, e.g. a special diet instead of oncology drugs; no special diet, food, vitamin or mineral is proven to slow or cure cancer; patients should tell their doctor about CAM use.
  • ASCO: Exercise, Diet, and Weight Management During Cancer Treatment (PMID 35576506) (2022) · Original publication
    Exercise recommended during curative treatment; neutropenic diets not recommended; evidence for other dietary and weight-loss interventions during treatment very limited (abstract).
  • ESPEN: ESPEN guidelines on nutrition in cancer patients (I-INTA-09, PMID 27637832) (2017) · Original publication
    Screen all cancer patients for malnutrition and meet energy and protein needs, except at end of life (as recorded for I-INTA-09; abstract).
  • WHO: Cancer - fact sheet (2026) · Original publication
    About 38% of cancers can be prevented by avoiding risk factors (tobacco, alcohol, unhealthy diet, inactivity, air pollution); about 10% are attributable to infections; many cancers can be cured if detected early and treated effectively.
  • ESMO: Statement on alternative medicine replacing cancer treatment could not be retrieved; content not used
  • NCCN: NCCN Guidelines (require login) · Original publication could not be retrieved; content not used
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026(diet OR "dietary intervention" OR "ketogenic") AND (cancer OR tumor) AND (survival OR "tumor response" OR remission) AND (PUB_TYPE:"Systematic Review" OR PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis") AND PUB_YEAR:[2018 TO 2026]supporting evidence3756
Europe PMC26 October 2026TITLE:(ketogenic) AND TITLE:(cancer OR tumor OR glioma OR glioblastoma) AND (randomized OR randomised) AND PUB_YEAR:[2015 TO 2026]supporting evidence114
Europe PMC26 October 2026("alternative medicine" OR "alternative therapy" OR "refusal of conventional" OR "refused treatment" OR "treatment refusal" OR "declined treatment") AND (cancer) AND (survival OR mortality) AND PUB_YEAR:[2017 TO 2026]contradicting evidence13958
Europe PMC26 October 2026("fasting mimicking" OR "fasting-mimicking") AND (chemotherapy) AND (randomized OR randomised OR trial)supporting evidence489
Europe PMC26 October 2026TITLE:"Exercise, Diet, and Weight Management During Cancer Treatment"guidelines2
Europe PMC26 October 2026(TITLE:"ESPEN" AND TITLE:"cancer") AND (guideline OR guidelines)guidelines8
Europe PMC26 October 2026(Tayebat OR Tayibat OR Elawady OR "El-Awady diet" OR "Al-Awady")both directions377
Europe PMC26 October 2026("complementary and alternative medicine" OR "herbal medicine" OR "traditional medicine") AND (cancer) AND (Egypt OR Egyptian OR Arab OR "Middle East")both directions5921
PubMed26 October 2026(diet therapy[MeSH Terms] OR "dietary intervention"[tiab]) AND neoplasms[MeSH Terms] AND (survival[tiab] OR "tumor response"[tiab]) AND randomized controlled trial[pt]supporting evidence36
PubMed26 October 2026("diet alone"[tiab] OR "dietary treatment"[tiab] OR "nutritional therapy"[tiab]) AND (cancer[tiab]) AND (remission[tiab] OR regression[tiab]) AND (cohort[tiab] OR trial[tiab])supporting evidence10
PubMed26 October 2026("alternative medicine"[tiab] OR "alternative therapy"[tiab]) AND (cancer[tiab]) AND (survival[tiab] OR mortality[tiab]) AND ("National Cancer Database"[tiab] OR cohort[tiab])contradicting evidence45
PubMed26 October 2026("refusal"[tiab] OR "declined"[tiab]) AND ("conventional treatment"[tiab] OR "standard treatment"[tiab] OR "chemotherapy"[tiab]) AND cancer[tiab] AND survival[tiab]contradicting evidence774
Web (WebFetch, NCI cancer.gov)26 October 2026https://www.cancer.gov/about-cancer/treatment/camguidelines1
Web (WebSearch)26 October 2026ESMO guideline complementary alternative medicine replace conventional cancer treatment statementguidelines9

Open questions

Outcomes of patients shown in the videos; Egyptian data on alternative-medicine use in cancer.

How deeply was this checked?

14 linked studies: 3 checked in full text (1 of them with a structured risk-of-bias assessment), 11 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: False (moderate)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: False (moderate)
    Unchanged. New 2026 registry studies (I-CAN-101, I-CAN-102) replicate the earlier finding in larger and more recent cohorts, and guidelines (I-CAN-105, I-CAN-106) confirm that no diet is proven to control cancer. Certainty stays moderate because all data on the specific diet are indirect and the cohorts share one registry.
    New sources: I-CAN-101 I-CAN-102 I-CAN-103 I-CAN-104 I-CAN-105 I-CAN-106 I-CAN-118 I-CAN-125 I-CAN-128 I-CAN-129 I-CAN-131

In plain language

Dr. Diaa said that cancer 'will respond' to his system and that a patient with a malignant tumour should start it immediately. There is no study showing that this diet treats cancer. Studies show that people who use alternatives instead of standard treatment die more often. Eating well can support patients, but only together with proper cancer treatment.

Studies on this claim

Studies supporting the claim (0)

No studies in this group.

Studies contradicting or limiting the claim (10)

  • Patients who used only alternative medicine for curable cancer died more often

    Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
    Cohort studyindependent cross-checkabstract checked★ key study

    Risk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.

    Alternative-only approach worse

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare AM-only vs conventional treatment.

    How was the study done?

    Matched registry cohort.

    How many people, animals or samples were studied?

    840 matched patients.

    What was actually found?

    HR 2.50 for death.

    How large was the observed effect?

    HR 5.68 breast cancer.

    What do the results mean in everyday life?

    Replacing cancer treatment with alternatives is dangerous.

    What are the study's limitations?

    Observational.

    What does it say about Elawady's specific claim?

    Contradicts refusing therapy.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Effects of complementary approaches used alongside treatment.

    Scientific details →

  • Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death

    Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
    Cohort studyindependent cross-checkabstract checked★ key study

    Users of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.

    Risk mediated by refusing therapy

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Study CM and survival.

    How was the study done?

    Registry cohort.

    How many people, animals or samples were studied?

    258 vs 1,032.

    What was actually found?

    HR 2.08; explained by refusal.

    How large was the observed effect?

    5-y OS 82.2% vs 86.6%.

    What do the results mean in everyday life?

    Diet or other approaches alongside treatment are not the problem; replacing treatment is.

    What are the study's limitations?

    Observational.

    What does it say about Elawady's specific claim?

    Contradicts refusal advice.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Causal effect of any single CM.

    Scientific details →

  • Each month of delay in cancer treatment raises the risk of death

    Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087
    Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key study

    For example, every 4-week delay of breast surgery was linked to 8% higher mortality.

    Trying diet first delays treatment

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Quantify harm from delay.

    How was the study done?

    Meta-analysis.

    How many people, animals or samples were studied?

    1.27 million patients.

    What was actually found?

    Higher mortality with delay.

    How large was the observed effect?

    HR 1.06-1.08 per 4 weeks (surgery).

    What do the results mean in everyday life?

    Do not postpone recommended treatment.

    What are the study's limitations?

    Observational, mostly US registry data; valid only for delays of about 4-16 weeks; not suitable for predicting an individual's risk.

    What does it say about Elawady's specific claim?

    Safety.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    The effect of delays longer than 16 weeks or of refusing treatment altogether; the effect for every cancer type; proof of causation.

    Scientific details →

  • Breast cancer patients who used only alternative medicine died more often

    Ayoade OF et al.. JAMA Netw Open 2026 · PMID 41770560 · DOI 10.1001/jamanetworkopen.2026.0337
    Cohort studyindependent cross-checkfull text checked★ key study

    Using alternative medicine instead of standard treatment was linked to a 3.7-fold higher risk of death; skipping parts of treatment also raised risk.

    CAM alone AHR 3.67 vs standard therapy

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare survival with alternative medicine vs standard treatment in breast cancer.

    How was the study done?

    US national registry cohort, adjusted Cox models.

    How many people, animals or samples were studied?

    2.16 million women; 273 used alternative medicine only.

    What was actually found?

    Higher death risk with alternative medicine alone, similar to no treatment.

    How large was the observed effect?

    AHR 3.67 (3.03-4.44); 5-year survival 60.1% vs 85.4% (unadjusted).

    What do the results mean in everyday life?

    Replacing breast cancer treatment with alternatives is dangerous.

    What are the study's limitations?

    Observational; registry may miss much alternative-medicine use.

    What does it say about Elawady's specific claim?

    Contradicts the advice to treat cancer with a diet.

    Do the results apply to Germany and Europe?

    Moderate (US data; same principle in Europe).

    What can explicitly not be concluded from this study?

    Effects of complementary methods used alongside full standard treatment.

    Scientific details →

  • Gastrointestinal cancer: alternative medicine alone linked to more deaths

    Ekenze SO et al.. J Gastrointest Surg 2026 · PMID 42607749 · DOI 10.1016/j.gassur.2026.102552
    Cohort studyindependent cross-checkabstract checked★ key study

    Patients who used only alternative medicine had an 86% higher risk of death; those who combined it with standard care did not.

    CAM alone aHR 1.86; combined use aHR 1.00

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Survival with alternative medicine in GI cancers.

    How was the study done?

    US registry cohort.

    How many people, animals or samples were studied?

    1.5 million patients; 197 alternative-only.

    What was actually found?

    Alternative-only use linked to higher mortality.

    How large was the observed effect?

    aHR 1.86 (1.37-2.51).

    What do the results mean in everyday life?

    Do not replace cancer treatment with alternatives.

    What are the study's limitations?

    Small group; observational; overlaps with other NCDB studies.

    What does it say about Elawady's specific claim?

    Contradicts diet as cancer treatment; supports use only alongside treatment.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Whether any specific diet helps.

    Scientific details →

  • Ketogenic diet trials in cancer: little proven benefit

    Salido-Bueno B et al.. Nutr Bull 2024 · PMID 38923748 · DOI 10.1111/nbu.12693
    Meta-analysisindependent cross-checkabstract checked

    In 7 small randomised trials, a ketogenic diet lowered blood glucose but did not clearly improve other cancer-related measures.

    No convincing effect of a ketogenic diet in RCTs

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Assess ketogenic diet effects in cancer RCTs.

    How was the study done?

    Meta-analysis of RCTs.

    How many people, animals or samples were studied?

    8 RCTs of 4-16 weeks.

    What was actually found?

    Only glucose fell.

    How large was the observed effect?

    Not quantified in abstract.

    What do the results mean in everyday life?

    No diet has been shown to treat cancer.

    What are the study's limitations?

    Small, short trials.

    What does it say about Elawady's specific claim?

    Contradicts diet-as-treatment claims.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Long-term effects.

    Scientific details →

  • US cancer doctors' guideline: exercise helps, diet evidence weak

    Ligibel JA et al.. J Clin Oncol 2022 · PMID 35576506 · DOI 10.1200/JCO.22.00687
    Guideline / position statementindependent cross-checkabstract checked★ key study

    ASCO found that exercise helps during cancer treatment but that evidence for specific diets is very limited.

    Diet evidence for cancer control very limited

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Guide exercise, diet and weight during cancer treatment.

    How was the study done?

    Systematic review plus expert panel.

    How many people, animals or samples were studied?

    52 reviews and 23 RCTs.

    What was actually found?

    Exercise helps; no diet shown to control cancer.

    How large was the observed effect?

    Not applicable.

    What do the results mean in everyday life?

    Diet can support, not replace, treatment.

    What are the study's limitations?

    Few diet trials.

    What does it say about Elawady's specific claim?

    Contradicts diet as cancer cure.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Absence of effect for all diets.

    Scientific details →

  • US National Cancer Institute: no diet is proven to control cancer

    National Cancer Institute. cancer.gov (NCI, US National Institutes of Health) 2024
    Guideline / position statementindependent cross-checkabstract checked★ key study

    The NCI states that no special diet has been proven to slow or cure cancer.

    No special diet proven to control cancer

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Inform patients about CAM.

    How was the study done?

    Agency summary.

    How many people, animals or samples were studied?

    Not applicable.

    What was actually found?

    No diet proven to control cancer.

    How large was the observed effect?

    Not applicable.

    What do the results mean in everyday life?

    Talk to the oncology team before using any diet against cancer.

    What are the study's limitations?

    Summary page.

    What does it say about Elawady's specific claim?

    Contradicts the claim.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Detailed evidence grading.

    Scientific details →

  • WHO: many cancers are preventable and curable

    World Health Organization. who.int 2026
    Guideline / position statementindependent cross-checkabstract checked

    About 38% of cancers can be prevented by avoiding risk factors, and many can be cured with early, effective treatment.

    Many cancers curable when treated effectively

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Summarise cancer facts.

    How was the study done?

    Agency fact sheet.

    How many people, animals or samples were studied?

    Global.

    What was actually found?

    Preventable external causes; curable with treatment.

    How large was the observed effect?

    38% preventable.

    What do the results mean in everyday life?

    Avoid tobacco and alcohol; get treated early.

    What are the study's limitations?

    Summary.

    What does it say about Elawady's specific claim?

    Contradicts 'not caused by external agents'.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Detailed estimates.

    Scientific details →

  • Refusing colon cancer surgery linked to much shorter survival

    Kaltenmeier C et al.. Am J Surg 2020 · PMID 32680623 · DOI 10.1016/j.amjsurg.2020.04.022
    Cohort studyindependent cross-checkabstract checked

    Patients who refused recommended surgery lived a median of 6.8 months vs 24 months.

    Refusing curative surgery: HR 3.41; median survival 6.8 vs 24 months

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Effects of refusing surgery.

    How was the study done?

    Registry cohort.

    How many people, animals or samples were studied?

    924,290 patients.

    What was actually found?

    Much worse survival after refusal.

    How large was the observed effect?

    HR 3.41.

    What do the results mean in everyday life?

    Do not delay or refuse curative treatment.

    What are the study's limitations?

    Observational.

    What does it say about Elawady's specific claim?

    Contradicts the claim.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Reasons for refusal.

    Scientific details →

Studies with mixed or unclear results (4)

  • Ketogenic diets in cancer patients: some metabolic benefits

    Zhang M et al.. Front Nutr 2025 · PMID 40756563 · DOI 10.3389/fnut.2025.1535921
    Meta-analysisindependent cross-checkabstract checked

    Ketogenic diets lowered body fat, insulin and glucose and improved some symptoms; survival was not shown to improve.

    Diet changes metabolic/symptom outcomes alongside therapy; no survival evidence

    Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Effect of ketogenic diets in cancer patients.

    How was the study done?

    Systematic review and meta-analysis.

    How many people, animals or samples were studied?

    Cancer patients in controlled studies.

    What was actually found?

    Better metabolic and some quality-of-life measures.

    How large was the observed effect?

    Not quantified in abstract.

    What do the results mean in everyday life?

    A diet can affect how patients feel and some blood values.

    What are the study's limitations?

    Surrogate outcomes; small studies.

    What does it say about Elawady's specific claim?

    Does not show that a diet treats cancer.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    That any diet cures or controls cancer.

    Scientific details →

  • Ketogenic diet added to chemotherapy for pancreatic cancer: early trial

    Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    In 32 patients, adding a supervised ketogenic diet to chemotherapy showed a trend toward longer survival that was not statistically confirmed.

    Diet added to chemotherapy: non-significant trends; not tested as replacement

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test a ketogenic diet added to chemotherapy.

    How was the study done?

    Randomised phase II trial.

    How many people, animals or samples were studied?

    32 patients.

    What was actually found?

    Trends toward longer PFS/OS.

    How large was the observed effect?

    PFS HR 0.53 (0.21-1.37).

    What do the results mean in everyday life?

    Diet research in cancer is about adding to treatment, not replacing it.

    What are the study's limitations?

    Small; uncertain; COI.

    What does it say about Elawady's specific claim?

    Does not support diet instead of treatment.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Any proven survival benefit.

    Scientific details →

  • Critique: registry 'CAM' is really alternative treatment instead of standard care

    Jeitler M et al.. Oncologist 2026 · PMID 42135607 · DOI 10.1093/oncolo/oyag187
    Otherindependent cross-checkfull text checked★ key study

    Experts note that the US registry studies capture people who used non-medical alternatives as cancer treatment, not complementary therapies in general.

    Methodological limits of NCDB CAM studies; affirms concern about treatment substitution

    Does the study support the specific claim? Unclear · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Critique NCDB CAM studies.

    How was the study done?

    Commentary.

    How many people, animals or samples were studied?

    Not applicable.

    What was actually found?

    Exposure narrow; some methods unclear.

    How large was the observed effect?

    Not applicable.

    What do the results mean in everyday life?

    The warning applies to replacing treatment, not to supportive therapies.

    What are the study's limitations?

    No new data.

    What does it say about Elawady's specific claim?

    Sharpens, does not weaken, the safety message.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Precise size of harm.

    Scientific details →

  • A low-fat diet alongside breast cancer treatment may reduce relapse

    Chlebowski RT et al.. J Natl Cancer Inst 2006 · PMID 17179478 · DOI 10.1093/jnci/djj494
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    Women who cut dietary fat while receiving standard treatment had somewhat fewer relapses (9.8% vs 12.4%), but the result was borderline.

    Diet as adjunct to conventional treatment: HR 0.76 for relapse (borderline)

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test low-fat diet after breast cancer surgery.

    How was the study done?

    Randomised trial.

    How many people, animals or samples were studied?

    2,437 women.

    What was actually found?

    Fewer relapses with diet (borderline).

    How large was the observed effect?

    HR 0.76 (0.60-0.98).

    What do the results mean in everyday life?

    Diet may help alongside treatment, not instead of it.

    What are the study's limitations?

    Interim; borderline.

    What does it say about Elawady's specific claim?

    Does not support diet as replacement.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    That any diet cures cancer.

    Scientific details →

Regional context

Germany / EU

Not region-specific; the evidence on the harms of replacing or delaying cancer treatment (I-CHM-03, I-CHM-04, I-CHM-07) applies equally in Germany and Europe.

Egypt

Not region-specific; the same risks apply. The videos address mainly Egyptian and Arab patients, so the claim is practically relevant there.

What applies in my country?

General scientific assessment

False This claim is false: no diet, including the Tayebat system, has been shown to treat cancer, and using it instead of standard treatment is associated with markedly higher mortality.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
  2. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
  3. Mortality due to cancer treatment delay: systematic review and meta-analysis.. Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087
  4. Use of Complementary and Alternative Medicine in the Management of Breast Cancer.. Ayoade OF et al.. JAMA Netw Open 2026 · PMID 41770560 · DOI 10.1001/jamanetworkopen.2026.0337
  5. Complementary and alternative medicine use: impact on survival among patients with gastrointestinal cancers.. Ekenze SO et al.. J Gastrointest Surg 2026 · PMID 42607749 · DOI 10.1016/j.gassur.2026.102552
  6. Effects of ketogenic diets on cancer-related variables: A systematic review and meta-analysis of randomised controlled trials.. Salido-Bueno B et al.. Nutr Bull 2024 · PMID 38923748 · DOI 10.1111/nbu.12693
  7. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.. Ligibel JA et al.. J Clin Oncol 2022 · PMID 35576506 · DOI 10.1200/JCO.22.00687
  8. Complementary and Alternative Medicine (CAM) for cancer - patient information page. National Cancer Institute. cancer.gov (NCI, US National Institutes of Health) 2024
  9. Cancer - WHO fact sheet. World Health Organization. who.int 2026
  10. Refusal of cancer-directed treatment by colon cancer patients: Risk factors and survival outcomes.. Kaltenmeier C et al.. Am J Surg 2020 · PMID 32680623 · DOI 10.1016/j.amjsurg.2020.04.022
  11. Impact of ketogenic diets on cancer patient outcomes: a systematic review and meta-analysis.. Zhang M et al.. Front Nutr 2025 · PMID 40756563 · DOI 10.3389/fnut.2025.1535921
  12. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.. Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343
  13. When "CAM" is not CAM: Interpreting national cancer database analyses in breast cancer.. Jeitler M et al.. Oncologist 2026 · PMID 42135607 · DOI 10.1093/oncolo/oyag187
  14. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.. Chlebowski RT et al.. J Natl Cancer Inst 2006 · PMID 17179478 · DOI 10.1093/jnci/djj494

← Back to overview